Cambridge, UK: TAP Biosystems, (the new corporate identity of The Automation Partnership), a leading supplier of innovative automation and consumables for life science applications, is delighted to announce it is currently working on projects to install six Cellmate™ automated cell culture systems in three of the world’s leading biopharma companies, where they will improve reproducibility and throughput of biotherapeutics manufacturing.
TAP Biosystems’ Cellmate is an established system that automates the processing of cells in roller bottles and T-flasks. To date over 80 systems have been installed world-wide. The latest six systems purchased by three international pharmaceutical companies will be installed to increase the manufacturing capacity of vaccines and protein-based therapies from adherent cell lines.
The pharmaceutical companies chose to install Cellmate systems because the automation improves reproducibility, reduces the risk of contamination and increases productivity. In addition, as Cellmate emulates the manual handling of roller bottle and T-flask cell culture, taking cell culturing from the lab to high volume production without process change. The Cellmates come with software designed to support the validation of the system for compliance with 21 CFR Part 11 and TAP provides full support for IQ and OQ, which makes integrating the Cellmates into the GMP facilities at these firms a straightforward task.
Tim Ward, Cellmate Product Manager at TAP Biosystems commented: "Many bioprocesses continue to use adherent cell lines that have proven difficult to adapt into stirred tank bioreactors. In such circumstances Cellmate provides a cost effective scale-up option and avoids the expense and time of developing and implementing new cell lines more amenable to suspension culture.”
Ward added: “We are delighted that these three top biopharma companies have taken advantage of the technical and strategic benefits that using a Cellmate can bring. Their confidence in this technology is a great endorsement of the Cellmate as an unrivalled method for cost-effective and reproducible manufacturing of specific types of vaccines, biotherapeutics and cell therapies.”
For Further Information Contact:
Matthew Walker, Head of Communications, TAP Biosystems, York Way, Royston,
Hertfordshire, SG8 5WY, UK. Tel: +44 (0) 1763 227200
Fax: +44 (0) 1763-227201 Email: [email protected]
Web: www.tapbiosystems.com
Editor Contact:
Dr Sue Pearson, Director, International Science Writer, PO Box 170, Hitchin,
Hertfordshire, SG5 3GD, UK.
Tel/Fax + 44 (0) 1462-635327 Email: [email protected]
Note to Editors
About TAP Biosystems
TAP Biosystems (the new corporate identity of The Automation Partnership) provides advanced automation systems and services to improve productivity in life science research, development and production.
For over 20 years TAP Biosystems has been the leader in the design and development of automated cell culture and processing systems with applications in bioprocessing, drug discovery and regenerative medicine. Systems include ambr, CellBase CT, CompacT SelecT, Polar and RAFT.
In addition, TAP Biosystems has a strong track record in providing a range of custom automation solutions for biobanking, biological sample management, compound management and advanced high throughput screening applications.
TAP Biosystems is a privately-owned company with headquarters near Cambridge, UK and a sales and support facility near Wilmington, Delaware, USA. www.tapbiosystems.com